2-(Piperazin-1-yl)pyridin-4-ylboronic acid | 1003043-70-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 2-(Piperazin-1-yl)pyridin-4-ylboronic acid
• 英文别名: (2-piperazin-1-ylpyridin-4-yl)boronic acid
• CAS: 1003043-70-6
• 化学式: C₉H₁₄BN₃O₂
• 分子量: 207.04
• InChiKey: IEBALFFRORMFKN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.83
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  68.6
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-(5-chloro-2-trifluoromethyl-benzyl)-7-iodo-1,2,3,4-tetrahydro-pyrido[2,3-b]pyrazine 、 2-(Piperazin-1-yl)pyridin-4-ylboronic acid 、 生成 1-(5-chloro-2-trifluoromethyl-benzyl)-7-(2-piperazin-1-yl-pyridin-4-yl)-1,2,3,4-tetrahydro-pyrido[2,3-b]pyrazine
  参考文献：
  名称：

  Pyridopyrazines and derivatives thereof as ALK and c-MET inhibitors

  摘要：

  本发明提供了公式I的化合物或其药学上可接受的盐形式，其中A，L1，R1，R2，R3，R4，R5，R6和X的定义如本文所述。公式I的化合物具有ALK和/或c-Met抑制活性，并可用于治疗ALK或c-Met介导的疾病或病况。

  公开号：

  US07919502B2

文献信息

• Pyridopyrazines and derivatives thereof as alk and c-Met inhibitors
  申请人：Dorsey D. Bruce

  公开号：US20080032972A1

  公开（公告）日：2008-02-07

  The present invention provides a compound of Formula I or a pharmaceutically acceptable salt form thereof, wherein A, L 1 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and X are as defined herein. The compounds of Formula I have ALK and/or c-Met inhibitory activity, and may be used to treat ALK- or c-Met-mediated disorders or conditions.

  本发明提供了化合物I的结构或其药学上可接受的盐形式，其中A、L1、R1、R2、R3、R4、R5、R6和X的定义如本文所述。化合物I具有ALK和/或c-Met抑制活性，并可用于治疗ALK或c-Met介导的疾病或病症。
• Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
  申请人：Cephalon, Inc.

  公开号：US08080561B2

  公开（公告）日：2011-12-20

  The present invention provides a compound of Formula I or a pharmaceutically acceptable salt form thereof, wherein A, L1, R1, R2, R3, R4, R5, R6, and X are as defined herein. The compounds of Formula I have ALK and/or c-Met inhibitory activity, and may be used to treat ALK- or c-Met-mediated disorders or conditions.

  本发明提供了公式I的化合物或其药学上可接受的盐形式，其中A，L1，R1，R2，R3，R4，R5，R6和X的定义如本文所述。公式I的化合物具有ALK和/或c-Met抑制活性，并可用于治疗ALK或c-Met介导的疾病或病况。
• Pyridopyrazines and derivatives thereof as ALK and c-MET inhibitors
  申请人：Cephalon, Inc.

  公开号：US07919502B2

  公开（公告）日：2011-04-05

  The present invention provides a compound of Formula I or a pharmaceutically acceptable salt form thereof, wherein A, L1, R1, R2, R3, R4, R5, R6, and X are as defined herein. The compounds of Formula I have ALK and/or c-Met inhibitory activity, and may be used to treat ALK- or c-Met-mediated disorders or conditions.

  本发明提供了公式I的化合物或其药学上可接受的盐形式，其中A，L1，R1，R2，R3，R4，R5，R6和X的定义如本文所述。公式I的化合物具有ALK和/或c-Met抑制活性，并可用于治疗ALK或c-Met介导的疾病或病况。
• THERAPEUTIC COMPOUNDS
  申请人：Gilead Sciences, Inc.

  公开号：US20130281433A1

  公开（公告）日：2013-10-24

  Compounds disclosed herein including compounds of formula I′: and salts thereof are provided. Pharmaceutical compositions comprising compounds disclosed herein, processes for preparing compounds disclosed herein, intermediates useful for preparing compounds disclosed herein and therapeutic methods for treating an HIV infection using compounds disclosed herein are also provided.

  本文披露了化合物，包括式I'的化合物及其盐。提供了包含本文披露的化合物的药物组合物，制备本文披露的化合物的方法，用于制备本文披露的化合物的中间体以及使用本文披露的化合物治疗HIV感染的治疗方法。
• Therapeutic compounds
  申请人：Gilead Sciences, Inc.

  公开号：US08987250B2

  公开（公告）日：2015-03-24

  Compounds disclosed herein including compounds of formula I′: and salts thereof are provided. Pharmaceutical compositions comprising compounds disclosed herein, processes for preparing compounds disclosed herein, intermediates useful for preparing compounds disclosed herein and therapeutic methods for treating an HIV infection using compounds disclosed herein are also provided.

  本文提供了包括式I′的化合物及其盐。还提供了含有本文所披露的化合物的药物组合物，制备本文所披露的化合物的方法，用于制备本文所披露的化合物的中间体以及使用本文所披露的化合物治疗HIV感染的治疗方法。